ALN GO1

Drug Profile

ALN GO1

Alternative Names: ALNGO1

Latest Information Update: 03 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Glycolate oxidase expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Primary hyperoxaluria

Most Recent Events

  • 14 Aug 2017 Alnylam Pharmaceuticals plans a phase II trial for Primary hyperoxaluria in France, Germany, Israel, Jordan, Netherlands, United Arab Emirates, United Kingdom and USA (EudraCT2016-003134-24)
  • 12 Jun 2017 Alnylam Pharmceuticals receives patent allowance for GalNac conjugation technique in USA
  • 27 Sep 2016 Initial safety and efficacy data from phase I/II trial in Primary hyperoxaluria were released by Alnylam
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top